[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-639395-105":59,"doc-detail-639395-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-and-experimental-neuroimmunology-original-article-background-analysis-of-the-initial-116-cases","Clinical and Experimental Neuroimmunology - Original Article - Background Analysis of the Initial 116 Cases","","Objectives focus on describing baseline clinical characteristics of patients with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) enrolled in the Japan registry and evaluating how representative each condition is for the Japanese population. Methods use a prospective multicenter observational design across 10 neurology referral centers, with annual clinical data, treatment history, and biological sample collection. Analyses summarize descriptive clinical outcomes for registrations between Dec 20, 2023 and Jul 31, 2024.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-and-experimental-neuroimmunology-original-article-background-analysis-of-the-initial-116-cases/639395/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-and-experimental-neuroimmunology-original-article-background-analysis-of-the-initial-116-cases/639395.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-10-22",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of the study in the Japan NMOSD/MOGAD Registry?","Question",{"text":112,"@type":113},"To describe baseline clinical characteristics of NMOSD and MOGAD patients enrolled in the registry and assess representativeness for the Japanese population.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the registry study conducted and what data were collected?",{"text":117,"@type":113},"A prospective multicenter observational design enrolled patients at 10 neurology referral centers. Clinical data, treatment history, and biological samples were collected annually.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key clinical findings for NMOSD and MOGAD patients?",{"text":121,"@type":113},"Among 116 analyzed patients, NMOSD accounted for 110 and MOGAD for 6. NMOSD showed older onset (mean 50.0 years), strong female predominance (89.1%), high AQP4 seropositivity (93.6%), and frequent relapsing course (67.3%). MOGAD showed younger onset (mean 27.3 years), all AQP4? (presented as MOG antibody seropositive), visual symptom predominance, and a median EDSS of 2.25.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},639395,1792789772,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Clinical and Experimental Neuroimmunology   \n ORIGINAL ARTICLE  \nThe Japan Neuromyelitis Optica Spectrum Disorders/Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Registry: Background Analysis of the Initial 116 Cases  \nYusei Miyazaki1  | Hideyuki Takeuchi2 | Takao Kiriyama3 | Hikoaki Fukaura4 | Juichi Fujimori5  | Katsuhisa Masaki6  | Sonoko Misawa7,8 | Katsuichi Miyamoto9  | Nobuaki Yoshikura10 | Shoko Ukita11 | Kengo Nagashima11  | Ichiro Nakashima5   \n1Department of Neurology, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan | 2Department of Neurology, Graduate School of Medicine, International University of Health and Welfare, Atami, Japan | 3Department of Neurology, Nara Medical University, Nara, Japan | 4Department of Neurology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan | 5Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan | 6Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka,  \nJapan | 7Department of Neurology and Neurological Science, Institute of Science Tokyo, Tokyo, Japan | 8Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan | 9Department of Neurology, Wakayama Medical University, Wakayama, Japan | 10Department of Neurology, Gifu University Graduate School of Medicine, Gifu, Japan | 11Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan  \nCorrespondence: Yusei Miyazaki ([miyazaki.yusei.hc@mail.hosp.go.jp](miyazaki.yusei.hc@mail.hosp.go.jp))  \nReceived: 9 June 2025 | Revised: 19 August 2025 | Accepted: 15 September 2025  \nFunding: This work was supported by Health and Labour Sciences Research Grant on Intractable Diseases (Neuroimmunological Diseases) from the Ministry of Health, Labour and Welfare of Japan (23FC1009). This study was also funded by Chugai Pharmaceutical Co. Ltd.  \nKeywords: biological specimens | monoclonal antibodies | myelin oligodendrocyte glycoprotein antibody-associated disease | neuromyelitis optica spectrum disorders | registries  \nABSTRACT  \nObjectives: To describe the baseline clinical characteristics of patients with neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) enrolled in the Japan NMOSD/MOGAD Registry (UMIN000051988) and to assess their representativeness of both conditions in the Japanese population.  \nMethods: This prospective multicenter observational registry study was conducted at 10 neurology referral centers in Japan. Patients with NMOSD or MOGAD were enrolled based on established diagnostic criteria. Clinical data, treatment history, and biological samples were collected annually. The present analysis includes patients registered between December 20, 2023 and July 31, 2024. Descriptive statistics were used to summarize the clinical data.  \nResults: A total of 116 patients (NMOSD, n = 110; MOGAD, n = 6) were analyzed. Among NMOSD patients, the mean age at onset was 50.0 years, and 89.1% were female. Most were anti-aquaporin 4 antibody seropositive (93.6%) . The median Expanded Disability Status Scale (EDSS) was 3.5%, and 67.3% had a relapsing course. Biologic agents were used in 63.6% of NMOSD patients. Among MOGAD patients, the mean age at onset was 27.3 years, and all were anti-myelin oligodendrocyte glycoprotein antibody seropositive. Visual symptoms predominated, and the median EDSS was 2.25.  \n\n| All the authors concur with the submission, and the material in the paper has not been previously reported and is not under consideration for publication elsewhere. |\n| --- |\n| © 2025 Japanese Society for Neuroimmunology. |\n\nClinical and Experimental Neuroimmunology, 2025; 0:1–9 1  \n[https://doi.org/10.1111/cen3.70032](https://doi.org/10.1111/cen3.70032)  \nConclusions: The clinical characteristics of NMOSD patients in the registry are consistent with prior epidemiologic","cbCaijjfqQLaWlgy","https://ap.wps.com/l/cbCaijjfqQLaWlgy","pdf",562979,"English","# Abstract\n## Objectives\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Background on NMOSD and MOGAD\n## Need for registry-based real-world evidence","[{\"question\":\"What is the main objective of the study in the Japan NMOSD/MOGAD Registry?\",\"answer\":\"To describe baseline clinical characteristics of NMOSD and MOGAD patients enrolled in the registry and assess representativeness for the Japanese population.\"},{\"question\":\"How was the registry study conducted and what data were collected?\",\"answer\":\"A prospective multicenter observational design enrolled patients at 10 neurology referral centers. Clinical data, treatment history, and biological samples were collected annually.\"},{\"question\":\"What were the key clinical findings for NMOSD and MOGAD patients?\",\"answer\":\"Among 116 analyzed patients, NMOSD accounted for 110 and MOGAD for 6. NMOSD showed older onset (mean 50.0 years), strong female predominance (89.1%), high AQP4 seropositivity (93.6%), and frequent relapsing course (67.3%). MOGAD showed younger onset (mean 27.3 years), all AQP4? (presented as MOG antibody seropositive), visual symptom predominance, and a median EDSS of 2.25.\"}]","Clinical and Experimental Neuroimmunology - Original Article - Background Analysis of the Initial 116 Cases | PDF",1792703420,23]